人肝
毒性
肝毒性
体内
药品
肝细胞
药物发现
肝功能
药理学
高通量筛选
肝功能检查
生物
计算生物学
体外
生物信息学
医学
内科学
生物化学
生物技术
作者
Shu Yang,Masato Ooka,Ryan Jared Margolis,Menghang Xia
标识
DOI:10.1016/j.crmeth.2023.100432
摘要
Drug-induced hepatotoxicity is a leading cause of drug withdrawal from the market. High-throughput screening utilizing in vitro liver models is critical for early-stage liver toxicity testing. Traditionally, monolayer human hepatocytes or immortalized liver cell lines (e.g., HepG2, HepaRG) have been used to test compound liver toxicity. However, monolayer-cultured liver cells sometimes lack the metabolic competence to mimic the in vivo condition and are therefore largely appropriate for short-term toxicological testing. They may not, however, be adequate for identifying chronic and recurring liver damage caused by drugs. Recently, several three-dimensional (3D) liver models have been developed. These 3D liver models better recapitulate normal liver function and metabolic capacity. This review describes the current development of 3D liver models that can be used to test drugs/chemicals for their pharmacologic and toxicologic effects, as well as the advantages and limitations of using these 3D liver models for high-throughput screening.
科研通智能强力驱动
Strongly Powered by AbleSci AI